Mirae

Mirae Therapeutics is a South Korean biotechnology company specializing in the development of microRNA (miRNA)-based therapeutics. Founded in 2020, the company leverages its proprietary MiRAE platform to discover and develop treatments for diseases with high unmet medical needs, particularly in regenerative medicine and fibrosis. Its lead program, MR-101, is a first-in-class miRNA therapy targeting androgenetic alopecia, currently in clinical development. The company's pipeline also includes candidates for non-alcoholic steatohepatitis (NASH) and various organ-specific fibrotic conditions. Mirae Therapeutics aims to harness the power of RNA regulation to restore cellular function and promote tissue regeneration.